During its annual business review Tuesday, Johnson & Johnson announced that the recent introduction of the OneTouch Verio Glucose testing platform represented one of the first diabetes care devices to alert and display high/low patterns that deliver more meaningful and actionable insights to help patients better understand and manage their diabetes.
Blood glucose monitoring is associated with reduced A1C levels and greater adherence to medication in Type 2 diabetes patients who do not take insulin, according to a study published in the September issue of Diabetes Technology & Therapeutics.
A drug marketed by Boehringer Ingelheim Pharmaceuticals and Eli Lilly reduced blood sugar in elderly patients with Type 2 diabetes and in adults with diabetic nephropathy, according to results of three studies presented at a diabetes meeting in Berlin.
The life of a patient with diabetes is a juggling act to maintain good glycemic control — from daily blood-glucose testing to eating healthy and staying active. This is a complex and sometimes inconvenient task requiring significant commitment. Today, the American Diabetes Association estimates 60 percent of diabetes patients do not adhere to their treatment regimen.
An integrated wellness team approach to diabetes care can help patients not only improve their condition, but also lower their prescription costs, according to new research presented at the American Association of Clinical Endocrinologists’ 21st annual Scientific and Clinical Congress in Philadelphia.
Being overweight and obesity during adolescence are associated with a disproportionately higher risk for cardiovascular disease risk factors, especially prediabetes and diabetes, according to a study published in the journal Pediatrics.
When one of Amylin Pharmaceuticals' diabetes drugs is used with mealtime insulin, both Type 1 and Type 2 diabetes patients maintain blood sugar in the normal glucose range on a daily basis, according to two analyses presented at the 72nd Scientific Sessions of the American Diabetes Association.
An investigational insulin being developed by Novo Nordisk significantly reduced the rate of hypoglycemia at night in adults with Type 2 diabetes, according to results of a late-stage clinical trial presented at the 72nd Scientific Sessions of the American Diabetes Association.
It seems insulin production and beta cell functioning may persist despite the onset of Type 1 diabetes, according to research conducted at the Massachusetts General Hospital and published in the March issue of Diabetes Care.
Self-monitoring blood glucose levels in Type 2 diabetics not on an insulin regimen may contribute little to managing the disease, according to an analysis published online last month by The Cochran Library.